Novartis Reports FDA's Acceptance of BLA for Brolucizumab (RTH258) to Treat Wet AMD
Shots:
- The BLA submission is based on P-III HAWK and HARRIER study results assessing brolucizumab (3/6 mg- q12w/q8w) vs aflibercept in 1800 patients with neovascular age-related macular degeneration nAMD or wet AMD at 400 sites
- P-III HAWK and HARRIER: @48wks. best-corrected visual acuity (BCVA) from baseline (6.6- 6.9 letters vs 6.8- 7.6 letters); patients with disease activity (23.5%- 21.9% vs 33.5%- 31.4%); key markers used by physicians to help guide management of the disease (31%- 26%)
- Brolucizumab (RTH258) is a single-chain antibody fragment (scFv) that inhibits VEGF receptors- with its expected launch in end of 2019. Novartis has utilized its Priority Review Voucher for brolucizumab’s FDA review
| Ref: Novartis | Image: Business Journal
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com